The S phase population in HT-29 cells (KRAS WT CRC) and HCT-116 cells (KRAS MT CRC), respectively, rose from 12.2% to 15.1% and from 10.6% to 17.8% compared to treatment with heteronemin alone (Figure 2A,B). Here, KRAS is linked to colorectal carcinoma.